Enoxaparin sodium biosimilar (Rovi)

依诺肝素钠生物类似药 (Rovi)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEnoxaparin sodium biosimilar (Rovi)
Drug Alias NameEnoxaparinum natricum (Rovi)依诺肝素钠生物仿制药 (Rovi)Arovi
ClassificationNatural product/Extract > Animal extractBiologics > Biosimilar
Mechanisms of ActionAntithrombin-III activatorsFactor Xa inactivationThrombin inactivation
TargetsAntithrombin-IIIProthrombinCoagulation factor X
Therapy Area/IndicationsVenous ThrombosisMyocardial InfarctionAngina, Unstable
Global Approved IndicationsVenous ThrombosisMyocardial InfarctionAngina, Unstable
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved Date2018/03/31
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesRovi
China Registration ClassN/A

Develop Information

Active CompaniesRovi
Inactive CompaniesRovi Pharmaceuticals Laboratories
Active IndicationsVenous ThrombosisMyocardial InfarctionAngina, Unstable
Inactive IndicationsN/A

Other Information

ATC CodeB01AB05
Related LinksN/A